康基医疗2024年度报告

Contents 2Chairman’s Statement4Corporate Information7Financial Highlights9Management Discussion and Analysis30Directors and Senior Management42Report of the Directors68Corporate Governance Report86Environmental, Social and Governance Report178Independent Auditor’s Report185Consolidated Statement of Profit or Loss and Other Comprehensive Income187Consolidated Statement of Financial Position189Consolidated Statement of Changes in Equity191Consolidated Statement of Cash Flows194Notes to Financial Statements297Definition Chairman’s Statement Dear Shareholders, 1,008.68.9%581.415.4% Despite the challenges faced in the past year, the Group achievedsatisfactory performance growth. During the Reporting Period, KangjiMedical achieved a revenue of RMB1,008.6 million, representing a year-on-year increase of approximately 8.9%, primarily attributed to increasedsales of disposable products. The profit attributable to owners of theparent company reached RMB581.4 million, representing a year-on-yearincrease of approximately 15.4%. 2024 In 2024, the Group made significant achievements in the nationwidecentralized VBP activities for hemostatic tissue ligation clips and wonthe bidding for a full range of ligation clip products, which laid a solidfoundation for the stable development of the Group’s business in thefuture. This nationwide centralized VBP is expected to further promoteimport substitution process, which will be conducive to further increasethe market share of the Company’s products. The Group’s overseasbusiness, benefiting from increased sales in the European market,also maintained a relatively good growth momentum. The Companywill continue to allocate resources to seize the opportunities arisingfrom centralized procurement in the PRC, and accelerate overseasproduct registration and market development, so as to consolidate thefoundation for sustainable development in the medium to long term. SR01-2002025 4 The Group not only maintained its leading foothold in minimally invasivesurgical instruments and consumables, but also made a strategicdeployment in the promising field of laparoscopic surgical robots. TheGroup’s strategic investment, Hangzhou Weijing Medical Robot Co.,Ltd., focuses on the application and promotion of intelligent platformfor minimally invasive surgery. Its independently developed four-armlaparoscopic surgical robot SR01-200 received approval from the NMPAin April 2025 and is well positioned for development. The Group will continue to accurately grasp market demand byupholding customer-centric approach, optimizing its product structureand strengthening academic initiatives, and deepen support, sharing anddissemination among healthcare professionals by organizing nationaland regional academic exchanges, so as to promote the development ofChina’s minimally invasive surgery industry. Looking ahead, the aging population and increasing adoption ofminimally invasive surgical procedures are expected to drive sustainedgrowth in the minimally invasive surgical instruments and consumablessector. Meanwhile, China’s accelerating healthcare reforms, includingthe expanded centralized VBP initiatives, will benefit the healthydevelopment of leading domestic brands in medical devices, therebypromoting R&D innovation and continuously contributing to thedevelopment of the industry. On behalf of the Board of directors, I would like to extend my sincereappreciation to our valued shareholders for their trust and support, andexpress heartfelt thanks to the management team and all employees fortheir dedicated efforts. The Group will actively implement its developmentstrategies and continuously enhance its business performance andcorporate management to create greater value for shareholders. Corporate Information BOARD OF DIRECTORS Executive Directors Mr. ZHONG Ming(Chairman)Ms. SHENTU YinguangMr. YIN Zixin Non-executive DirectorMs. CAI Li Independent Non-executive Directors Mr. JIANG FengMr. GUO JianMr. CHEN Weibo AUDIT COMMITTEE Mr. CHEN Weibo(Chairman)Mr. JIANG FengMs. CAI Li REMUNERATION COMMITTEE Mr. CHEN Weibo(Chairman)Ms. SHENTU YinguangMr. GUO Jian NOMINATION COMMITTEE Mr. ZHONG Ming(Chairman)Mr. JIANG FengMr. GUO Jian ENVIRONMENTAL, SOCIAL AND GOVERNANCECOMMITTEE Mr. ZHONG Ming(Chairman)Ms. SHENTU YinguangMr. YIN Zixin COMPANY SECRETARY Mr. WAN Siu Keung Corporate Information AUTHORIZED REPRESENTATIVES Mr. ZHONG MingMr. YIN Zixin AUDITOR 97927 Ernst & YoungCertified Public AccountantsRegistered Public Interest Entity Auditor27/F, One Taikoo Place979 King’s RoadQuarry BayHong Kong REGISTERED OFFICE Appleby Global Services (Cayman) Limited71 Fort StreetP.O. Box 500George TownGrand Cayman KY1-1106Cayman Islands Appleby Global Services (Cayman) Limited71 Fort StreetP.O. Box 500George TownGrand Cayman KY1-1106Cayman Islands CORPORATE HEADQUARTERS 1668 No. 1668 Chunjiang East RoadTonglu Economic Development ZoneHangzhouZhejiang ProvincePRC HONG KONG LEGAL ADVISER 50037 Clea